ViiV AFRICA PHARMACOVIGILANCE (PV) ENHANCEMENT PROJECT
WHAT?
The Project has been established to help strengthen PV across the African continent and to monitor the safe use of antiretroviral medicines.
WHY?
Collection and management of safety information helps build an accurate safety profile for medicines which in turn promotes public health and reduces the burden on healthcare systems.
Safety reporting in sub-Saharan Africa is far behind other parts of the world. The Africa PV enhancement project aims to help bridge the gap.
HOW?
Increasing Healthcare Professional's PV capabilities, and improving PV systems / infrastructure.
PHARMACOVIGILANCE (PV): THE ROLE OF HEALTHCARE PROFESSIONALS (HCPs)
HCPs have an important role to play in the management of safety information - we rely on HCPs to report adverse drug reactions (ADRs)/side effects to medicines. Reporting of ADRs has a proven role in identifying safety issues that in turn impacts patient management and leads to better patient outcomes.
Learn more about this project
GET IN THE KNOW!
Explore the below training materials to improve your knowledge in key topics related to Pharmacovigilance
Module 2 - Introduction to signal management
What is signal management? Learn more about the principles of signal detection, validation, prioritisation and assessment.
Module 3 - Benefit-Risk evaluation
Understand the fundamentals of benefit-risk assessment.
Module 4 - Safety communication in Pharmacovigilance
Take a look into various platforms and methods that are used to share important safety information with HCPs and the public.
Module 5 - Country specific PV training, including how to report Adverse Drug Reactions / Adverse Events.
Understand the process to report safety information in specific
African countries.
Have a question?
If you have a question about Pharmacovigilance in Africa contact us
NP-GBL-HVX-WCNT-240007 May 2024
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
